AcclaimIP-ad

Match Document Document Title
DE102006053635B4 New substituted with benzyl 1,4-Benzothiepin-1,1-dioxide derivatives, pharmaceutical compositions containing them and their use  
Compounds of formula and the pharmaceutically acceptable salts thereof.
DE102006053635A1 New substituted with benzyl 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use  
The Invention relates to the compounds of formula I and physiologically acceptable Salts. The connection is suitable for. B. as hypolipidemic agents.
DE102006053385B4 Enterococcus faecalis antigen  
Enterococcus faecalis strain type 5 antigen, at least one disaccharide unit comprising, having the following formula: where R1 OH, X = O, Y = O and CA lactyl is.
DE102006053385A1 Enterococcus faecalis and / or Enterococcus faecium antigen  
The This invention relates generally to the field of detection and prevention of infectious diseases caused by Enterococcus faecalis and / or Enterococcus faecium caused. In particular relates to...
DE102006035393A1 Prognostic markers for the classification of the three-year progessionsfreien survival of patients with colon cancer based on expression profiles of biological samples  
The Invention relates to the use of gene expression profiles for Predicting the three-year progression-free survival or recurrence of patients receiving colorectal cancer in UICC stage I or II was...
DE202005021489U1 A composition as for the synthesis of compounds phosphitylated  
Composition, containing a compound capable of forming enolates, and a phosphoramidite.
DE202005021488U1 Mixture of an activator and an additive for preparing phosphitylated compounds  
A Mixture of an activator having the formula I wherein R = alkyl, cycloalkyl, Aryl, aralkyl, heteroalkyl, heteroaryl R1. R2 = Either hydrogen or together form a 5- or 6-membered ring X1, X2 =...
DE112004002408B4 A process for obtaining an enriched population of siRNA-expressing cells  
process for obtaining cells which are capable of inhibiting RNA expressing, said method comprising: introducing at least one nucleic acid in a cell, wherein the at least one nucleic acid in the...
DE102006049821A1 New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues  
New metal chelates (I) (optionally in salt form) contain (a) perfluorinated polyethylene glycol (PEG) residue(s), (b) chelator residue(s) and (c) at least one equivalent of metal(s) of atomic...
DE102007016151A1 coated implant  
implant with a coating, wherein the implant is an amino-functionalized Parylene, an oligonucleotide and / or an oligopeptide comprising, which have a specific binding affinity for CD 34-positive...
DE102006042891A1 Breaking down of poly-, oligo-, disaccharide or its derivatives, useful as raw material e.g. in textile industry, comprises dissolving the derivatives in an ionic liquid and treating the mixture at an elevated temperature  
Method for breaking down of poly-, oligo-, disaccharide (I) or its derivative comprises dissolving (I) in an ionic liquid and treating the mixture at an elevated temperature, optionally in the...
DE102006042890A1 Silylating poly-, oligo-, disaccharides derivatives comprises dissolving the poly-, oligo- disaccharides in an ionic liquid and reacting the obtained mixture with a silylating agent  
Silylating poly-, oligo-, disaccharides or their derivatives comprises dissolving the poly-, oligo- disaccharides in an ionic liquid and reacting the obtained mixture with a silylating agent. An...
DE102006037786A1 Nucleosides, containing these drugs and their use  
The Invention relates to specific nucleosides, and drugs which these nucleosides contained. Furthermore, the invention relates to the Use of such nucleosides for the preparation of a medicament,...
DE102006039479A1 Programmable oligonucleotide  
The Invention relates to methods and apparatus for the preparation of synthetic nucleic acids.
DE102007007750A1 avermectin  
New Avermectin derivatives of the formula (I), in which -C22R1-AC23R2. R3, R4 and R5 the meanings indicated in the description have,Methods for preparing these substances and their use for...
DE102006037580A1 Sandel Perfume receptors  
The Invention relates to the field of olfactory receptors, the receptive influencing Medications and biosensors. The invention further relates to compounds of the general formula (I), in whichX...
DE102006037581A1 Citrusal Perfume receptors  
The Invention relates to the field of olfactory receptors, the empfängsnisbeeinflussenden Medications and biosensors.
DE102006035618A1 New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria  
Nucleic acid (I) is new. Nucleic acid of formula G lX mG n (I) is new. G = guanosine, uracil or an analog; X = guanosine, uracil, adenosine, thymidine, cytosine or an analog; l = 1-40; m >= 3; and...
DE102006032569A1 Silylating poly-, oligo-, disaccharides derivatives comprises dissolving the poly-, oligo- disaccharides in an ionic liquid and reacting the obtained mixture with a silylating agent  
Silylating poly-, oligo-, disaccharides or their derivatives comprises dissolving the poly-, oligo- disaccharides in an ionic liquid and reacting the obtained mixture with a silylating agent. An...
DE69133552C5 Deoxyribonucleic acid sequence encoding non-A, non-B hepatitis virus - obtd. Hutch C59 subgroup encoding polypeptide(s), useful as vaccines, and immuno reactive ABS for diagnosis of virus  
Sequence (I) comprises (a) the Hutch c59 DNA sequence shown in SEQ ID NO:46 of the spec; (b) degenerate sequences of the sequence of (a); (c) a mutant variant of the NANBV Hutch c59 strain with...
DE3890998B4 Neutrophilenaktivierungsfaktor, process for its preparation and pharmaceutical composition containing it  
Neutrophilenaktivierungsfaktor (NAF) which is derived from human monocytes and the following amino acid sequence comprising:...
DE102006029306A1 Silylation of polysaccharide, especially cellulose, to give products for use in the textiles, food, building and paint industries, involves dissolving in ionic liquid and reacting with a silylating agent  
A method for the silylation of poly-, oligo- or di-saccharides or their derivatives involves dissolving these compounds in ionic liquid(s) and reacting them with a silylating agent.
DE102006028165A1 A process for the acylation of cellulose  
The This invention describes a method for the acylation of Poly-, oligo- or disaccharides or derivatives thereof, by this in an ionic liquid triggers and reacted with a ketene, and new acylated...
DE102006025154A1 Mutated DNA polymerase with increased reverse transcriptase activity  
The This invention relates to a DNA polymerase with increased reverse Transcriptase activity, which compared to the wild-type variant at least one mutation in their amino acid sequence comprises,...
DE102006025153A1 Mutant DNA polymerases with higher selectivity  
The This invention relates to a DNA polymerase with increased mismatch discrimination, which compared to the wild-type variant at least one mutation in their amino acid sequence comprises, as well...
DE102006022569B4 Spezies-unabhängiges Nachweisverfahren für biologisches Material  
Verwendung mindestens eines ersten Primers zur DNA-Fingerprint-Analyse, wobei der mindestens erste Primer eine Sequenz enthält, die von einer 8 bp langen palindromischen oder GC-reichen Sequenz...
DE102006020885A1 Inserting a tag sequence into a nucleic acid comprises using an anchor oligonucleotide comprising a hybridizing anchor sequence and a nonhybridizing tag-template sequence  
Inserting a tag sequence into a nucleic acid comprises hybridizing an anchor sequence of an anchor oligonucleotide to a sequence segment of a template nucleic acid and synthesizing a new nucleic...
DE102006019480A1 Use of gene expression profiles to detect any postoperative tissue incompatibility reactions after liver transplantation  
Gene expression profiles obtained from a patient sample in vitro are used to detect any postoperative tissue incompatibility reactions after liver transplantation. An independent claim is also...
DE102007018551A1 Preparing gemcitabine comprises reducing a dihydro-furan-2-one compound to give a furan compound, activating the hydroxyl group and reacting with a protected cytosine to give a protected nucleoside and terminal protection of the nucleoside  
Preparation of gemcitabine comprises reducing a dihydro-furan-2-one compound (16A) to give a furan compound (19), activating the hydroxyl group by converting into a sulfonate (mesylate), reacting...
DE102006017492A1 Drug fixation on polymer surfaces  
Of the The present invention relates to compounds according to the general Formula 1, where R1. R2, R3, R4, R5, R6. R7, R8th, R9 and R10 independently selected are selected from the group...
DE202007003784U1 Apparatus for the purification of biomolecules  
device for the purification of biomolecules having by adsorptive separation in a a flat adsorbent (6) Chromatography module (2), the housing (3) at least one inlet (4) and at least one outlet (5)...
DE102006011077A1 A method for degradation of cellulose with nucleophiles  
The This invention describes a method for degradation of cellulose, by dissolving cellulose in an ionic liquid and with a nucleophile treated.
DE102006011076A1 Degradation of poly-, oligo- or di-saccharide or derivative e.g. partial degradation of cellulose for fiber or film production or complete degradation to glucose involves heating solution in ionic liquid e.g. quaternary ammonium compound  
Process for degradation of poly-, oligo- or di-saccharides or their derivatives comprises dissolving the material in ionic liquid(s) and treated at elevated temperature, optionally with addition...
DE102006011075A1 Process for the degradation of cellulose in solution  
The This invention describes a method for degradation of cellulose, by dissolving the cellulose in an ionic liquid and with an acid, optionally the addition of water, treated.
DE102006008701A1 Procedure for transferring biomolecules into a cell, comprises preparing a complex from biomolecule and polymer, and transferring the biomolecule into a cell by contacting the cell with the complex  
Procedure for transferring biomolecule into a cell, comprises preparing a complex from the biomolecule, preferably nucleic acid, and a polymer, which is obtained through reacting an amine-monomer...
DE20122767U1 Massive parallel method for decoding DNA and RNA  
On Nucleotide analogue which comprises: a) a base selected from the group consisting of adenine or an analogue of adenine, Cytosine or an analogue of cytosine, guanine or an analogue of Guanine,...
DE202007003503U1 Galatenoside and their use as antidepressants  
Polygalatenosid the following structure: comprising racemic mixtures of optically active compounds or optically pure R and S stereoisomers, in which R, R 'and R' 'independently H or R1 constitute,...
DE102006001759A1 Synthesis of metal nanoparticles and nanocrystals, useful particularly for silver disinfection of e.g. medical instruments, uses a silicatein protein, also new silicateins and nucleic acid encoding them  
Method for synthesizing nanoparticles and nanocrystals (X) from gold, silver and other transition metals that uses a protein (I), or its metal complex, where (I) comprises an animal, bacterial,...
DE19981703B4 A process for increasing the purity of the racemic form of metallocene  
process to increase the purity of the racemic form of metallocene complexes comprising the steps of (a) adding a compound of LiOH, NaOH and / or KOH or an amine and - water a mixture comprising a...
DE102005063244A1 New 2-nitroimidazole derivatives, useful for detecting hypoxic tissue especially associated with tumors, diabetes, stroke and/or circulatory diseases, have substituent that mediates transport into biological cells  
New 2-nitroimidazole derivatives (I) have a substituent (or vehicle) that mediates transport into biological cells via cellular transport systems. Independent claims are also included for the...
DE102005059242A1 Molecular markers for tumor diagnosis and therapy  
The This invention relates to the diagnosis, prognosis, monitoring and therapy of neoplastic diseases such as tumor diseases, in particular Cancers of the endometrium and their metastases.
DE102005058542A1 Erythruloseester as UV filters  
The Invention relates to compounds according to formula I, wherein X, Y and Z are O, NH or N-alkyl, Sp, Sp ', Sp' 'can be identical or different and are -H, - (CH2)n-, - (CH2)n-C (= O) - (CH2)O-...
DE102005058431A1 Nucleic acid useful as a target for detecting species of yeasts and/or filamentous fungi comprises an elongation factor 3 gene or a fragment thereof  
Nucleic acid (I) comprising the elongation factor 3 gene of yeasts and filamentous fungi or a fragment thereof is new. New nucleic acid (I) comprises a nucleic acid (Ia) with a sequence selected...
DE102005057334A1 A method for isolating nucleic acids from any starting materials  
object the invention is a universal and highly simplified procedure for isolating nucleic acids of nucleic acids containing diverse feedstocks using a combination from buffers with chaotropic...
DE102005046361A1 Detection and differentiation of Salmonella serovars, especially parathyphi B and Java, useful for analysis of e.g. food, clinical and water samples, based on amplification of gene STM3356  
Method for detecting and/or differentiating Salmonella serovars (A). Method for detecting and/or differentiating Salmonella serovars (A) comprises (i) amplifying a region of the STM3356 gene,...
DE102005047736A1 Method to isolate nucleic acid comprises protectively solubilizing biological sample in buffer, adding alcoholic component/non ionic detergent, binding nucleic acid to solid phase, washing with buffer and eluting with salt buffer/water  
Method for isolation of nucleic acid from nucleic acid material comprises protectively solubilizing biological sample in a previously known buffer solution, which is provided with no chaotropic or...
DE102005047736B4 Method and system for isolating nucleic acids from any complex starting materials  
systems without chaotropic and antichaotropic components for isolating nucleic acids from nucleic acids containing materials comprising • at least a per se known Buffer for proteolytic digestion...
DE102005033902B3 Perfluoroalkyl-containing complexes, processes for their preparation, and their use and pharmaceutical compositions containing them  
The Invention relates to the marked in the patent claims, namely perfluoroalkyl Metal complexes with nitrogen-containing groups of the general formula I, to processes for their preparation and...
DE102005046490A1 New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency  
Nucleic acid molecule comprising (in 5'-3' transcription direction) (a) a promoter; (b) a transcriptable nucleic acid sequence or a nucleic acid sequence for inserting in to a transcriptable...
DE102005042828A1 Selected CGPR antagonists, process for their preparation and their use as medicaments  
object the present invention relates to the CGRP-antagonists of general Formulas I, in which R1, R2 and R3 are as defined in claim 1, their Tautomers, the isomers, the diastereomers, deren...